Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Chronic Urticaria
NCT01803763Phase 3Completed
- Sponsor
- Insel Gruppe
- Start
- Sep 2012
- Primary completion
- Mar 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in chronic urticaria (CU), sponsored by Insel Gruppe. Started Sep 2012; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic urticaria (CU)
Beyond the preview
Go deeper on NCT01803763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01803763.